Hexarelin

Hexarelin — Potent GHRP Research Peptide

Hexarelin is a synthetic hexapeptide developed in the 1990s as a successor to earlier-generation GHRPs (GHRP-6 and GHRP-2). It acts as a potent agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by endogenous ghrelin — and is distinguished in research literature as one of the most potent GHRPs in its class on a per-weight basis. Hexarelin also has a uniquely well-documented research profile at the CD36 receptor, making it of particular interest in cardiac and vascular research models.

Mechanism of Action

Hexarelin has been investigated in published research for activity across several biological pathways, including:

• GHS-R1a receptor agonism — high-affinity binding to the growth hormone secretagogue receptor in the pituitary and hypothalamus
• Pulsatile GH release — research on amplitude-modulated growth hormone secretion patterns, with notably high peak amplitudes compared to other GHRPs in preclinical models
• CD36 receptor binding — Hexarelin is documented in research literature as one of the few GHRPs with significant binding affinity at the CD36 scavenger receptor, expressed in cardiac tissue, vasculature, and macrophages
• Cardiac research pathways — preclinical investigations into cardioprotective signaling and post-ischemic cardiac research models
• IGF-1 pathway research — downstream insulin-like growth factor-1 signaling
• Cortisol and prolactin pathway research — comparative research on off-target hormonal effects characteristic of first- and second-generation GHRPs
• Comparative GHRP pharmacology — comparative analysis alongside GHRP-6, GHRP-2, and Ipamorelin

Hexarelin is distinguished in research literature by two characteristics: its potency at the GHS-R relative to other GHRPs in its weight class, and its additional documented activity at the CD36 receptor. The CD36 pathway activity is particularly notable because it gives Hexarelin a dual-receptor research profile not shared by most other GHRPs, opening research applications in cardiac and vascular biology beyond standard GH-axis investigations.

Research Applications

Hexarelin is widely used in research contexts including:

• GHS-R receptor pharmacology and signaling studies
• Pulsatile GH release research models
• CD36 receptor binding and cardiac pathway research
• Cardiac ischemia and post-ischemic research models
• Vascular biology and macrophage research
• Comparative GHRP analysis alongside GHRP-6, GHRP-2, and Ipamorelin
• Combined-pathway GH-axis research alongside GHRH analogs such as CJC-1295 and Tesamorelin
• IGF-1 response and downstream signaling research

Product Specifications

• Compound: Hexarelin
• Form: Lyophilized white powder
• Purity: ≥99% (verified by HPLC and mass spectrometry)
• Available sizes: 10mg
• Third-party tested: Certificate of Analysis available on request

Reconstitution & Storage

Lyophilized Hexarelin should be stored at -20°C for long-term stability and protected from light. Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2–8°C and used within the timeframe indicated on the product COA. Avoid repeated freeze-thaw cycles, as they can degrade peptide integrity.

Shipping & Handling

All orders are shipped with temperature-controlled packaging to preserve peptide integrity. Domestic orders typically arrive within 2–4 business days. Tracking is provided on every order.

Important Disclaimer

This product is sold strictly for laboratory research and in-vitro use only. It is not intended for human or animal consumption, diagnostic use, therapeutic use, or any form of clinical application. By purchasing, you confirm that you are a qualified researcher or affiliated with a licensed research institution and that this product will be handled in accordance with all applicable laws and safety standards.

Hexarelin is not approved by the FDA for human use, and this product is not a substitute for any prescribed medication.